In vitro studies have also clarified the ability of CCN1 to overcome estrogen dependency and elicit resistance to the selective estrogen receptor (ER) modulators and down-regulators (SERMs/SERDs) tamoxifen and fulvestrant in ER-positive breast cancer cells [15–17, 29, 31]. Here, ESR1 is linked to breast carcinoma.